Acute Myeloblastic Leukemia (AML)

Acute myeloblastic leukemia (AML)—also called acute myeloid leukemia or acute non-lymphocytic leukemia—is a fast-growing blood and bone-marrow cancer that starts from immature myeloid cells. These cells should mature into healthy white cells, red cells, or platelets. In AML, gene changes make the cells grow without control and fail to mature. The marrow fills with blasts, crowding out normal blood-making. People then become anemic, prone to infections, and bleed easily. AML can spread to the blood, spleen, liver, lymph nodes, skin, gums, and the brain coverings. It needs urgent diagnosis and treatment. Modern care often combines chemotherapy, targeted pills, immunotherapy, and stem-cell transplantation. Care also focuses on preventing infections, supporting nutrition and strength, and managing symptoms kindly and quickly.

Acute myeloblastic leukemia (AML) is a fast-growing blood cancer that starts in the bone marrow, the soft tissue inside bones where new blood cells are made. In AML, immature myeloid “blast” cells multiply out of control. These blasts crowd out normal cells, so the body cannot make enough healthy red cells (to carry oxygen), white cells (to fight infection), or platelets (to stop bleeding). The result is tiredness, pale skin, breathlessness, frequent or serious infections, easy bruising, and bleeding. AML can worsen quickly without treatment, so prompt diagnosis and care are important. Doctors confirm AML with blood tests, a bone-marrow exam, and special studies that look at leukemia cell markers and genes. These tests also help decide the best treatment and the risk group. Cancer.gov

Other names

AML is also called acute myelogenous leukemia, acute myeloid leukemia, or historically acute non-lymphocytic leukemia (ANLL). Some older systems used “myeloblastic leukemia” for specific subtypes where the leukemia cells are mainly myeloblasts (for example, FAB M1 or M2). Modern classifications group AML by genetic features (such as t(8;21), inv(16), NPM1-mutated AML, or biallelic CEBPA-mutated AML), by therapy-related cause, and by changes that developed from earlier bone-marrow disease (like MDS). The newer World Health Organization (WHO) and International Consensus Classification (ICC) systems emphasize molecular and cytogenetic findings. PMCBioMed Central

Types

1) AML with recurrent genetic abnormalities. These are AMLs defined by specific chromosomal changes or gene fusions, such as t(8;21)/RUNX1::RUNX1T1 and inv(16)/t(16;16)/CBFB::MYH11. These genetic “flags” help diagnose the disease and often have prognostic value. PMC

2) NPM1-mutated AML. Here, the NPM1 gene is altered. It is common in adults and, without other high-risk features, often falls into a favorable-risk group with standard therapy. ASH Publications

3) Biallelic CEBPA-mutated AML. Both copies of the CEBPA gene are affected. This pattern is associated with better outcomes when treated promptly. ASH Publications

4) AML, myelodysplasia-related (AML-MR). This develops in people who had myelodysplastic syndromes (MDS) or show MDS-type changes in cells or carry MDS-related mutations. Prognosis is usually less favorable. PMC

5) Therapy-related AML (t-AML). AML that arises after prior chemotherapy or radiation for another illness. The leukemia cells often carry distinctive chromosome changes and tend to behave more aggressively. Cancer.gov

6) AML with other defining gene changes. Examples include RUNX1-mutated, TP53-mutated, FLT3-mutated AML and others; doctors check broad panels because these results steer treatment choices and clinical-trial options. ASH Publications

7) Myeloid sarcoma. Solid “tumors” of myeloid blasts outside the marrow (e.g., skin, lymph nodes, gut). They are treated as AML, often with the same regimens. PMC

8) AML, not otherwise specified (NOS) / FAB subtypes. When no defining genetic feature is found, cells may still be described by older FAB terms (M0–M7) such as myeloblastic with minimal maturation (M0), myeloblastic without/with maturation (M1/M2), myelomonocytic (M4/M4-Eo), monocytic (M5), erythroid (M6), and megakaryoblastic (M7). Nature

---

Causes

(In leukemia, “cause” usually means a risk factor. Many people with AML have no clear cause. Items below are known or suspected contributors.)

1) Age-related DNA damage. As we age, more random DNA changes build up in marrow stem cells. These can push a cell toward leukemia. AML is most common in older adults. Cancer.gov

2) Prior chemotherapy (alkylating agents). Some drugs used to cure other cancers later raise AML risk by damaging marrow DNA. This is called therapy-related AML. Cancer.gov

3) Prior chemotherapy (topoisomerase II inhibitors). Medicines like etoposide can cause specific DNA breaks that, years later, lead to AML. Cancer.gov

4) Radiation exposure. High-dose radiation, including older cancer treatments or major occupational/accidental exposures, increases AML risk. Cancer.gov

5) Benzene exposure. Long-term contact with benzene (certain industries, solvents, fuels) damages marrow and is a well-established AML risk. American Cancer Society

6) Cigarette smoking. Toxins enter the blood and reach the marrow; smoking is the only proven lifestyle AML risk. American Cancer Society

7) Myelodysplastic syndromes (MDS). AML can grow out of pre-existing MDS when abnormal clones gain more harmful mutations. PMC

8) Myeloproliferative neoplasms (MPN). Polycythemia vera, essential thrombocythemia, or myelofibrosis can transform into AML after years. PMC

9) Inherited bone-marrow failure syndromes: Fanconi anemia. This DNA-repair disorder strongly raises the risk of AML. PMC

10) Inherited predisposition: GATA2 deficiency. A germline GATA2 change can cause immune and marrow problems and higher AML risk. PMC

11) RUNX1 familial platelet disorder. Inherited RUNX1 changes cause platelet issues and a substantial AML risk over a lifetime. PMC

12) Down syndrome (trisomy 21). Children with Down syndrome can develop unique myeloid diseases and AML; adults have increased risk as well. PMC

13) Shwachman–Diamond syndrome. This inherited marrow failure condition raises MDS/AML risk. PMC

14) Li–Fraumeni syndrome (TP53). Germline TP53 mutations predispose to many cancers, including AML. PMC

15) Neurofibromatosis type 1 (NF1). Genetic changes in NF1 can increase risk of certain leukemias. PMC

16) Prior high-dose radiotherapy fields. Large-field or repeated radiation to marrow-rich bones accumulates risk beyond background exposure. Cancer.gov

17) Formaldehyde and some industrial chemicals. A body of occupational studies links certain chemical exposures to AML. PMC

18) Obesity. Excess body fat is associated with higher AML risk in some studies, possibly through inflammation and hormonal pathways. PMC

19) Long-term petroleum/solvent exposure. Some jobs (refining, printing, shoe/leather work) historically involved solvents related to leukemia risk. PMC

20) Clonal hematopoiesis in aging. “CHIP/CH” means some marrow cells carry driver mutations without cancer; a small fraction evolve into MDS/AML over time. ASH Publications

---

Symptoms

1) Tiredness and weakness. Too few red cells mean less oxygen delivery. People feel drained even after rest. Cancer.gov

2) Shortness of breath. Anemia makes climbing stairs or walking fast hard because muscles and organs get less oxygen. Cancer.gov

3) Pale skin. Low hemoglobin reduces the usual pink color of skin and inner eyelids. Cancer.gov

4) Frequent infections. The body lacks enough healthy neutrophils. Colds last longer, fevers are common, and infections can be severe. Cancer.gov

5) Fever. Fever may come from infection or from the leukemia itself causing inflammation. Cancer.gov

6) Easy bruising. Low platelets make bruises appear after small bumps, often on arms and legs. Cancer.gov

7) Bleeding gums or nosebleeds. Platelet shortage and fragile vessels cause mucosal bleeding, especially when brushing teeth. Cancer.gov

8) Tiny red spots (petechiae). These “pinpoint” skin dots are small bleeds from low platelets. Cancer.gov

9) Bone or joint pain. A crowded marrow can cause pressure and aching in long bones or sternum. Cancer.gov

10) Swollen gums (gingival hypertrophy). In some AML types (often monocytic), leukemia cells infiltrate the gums, making them thick and sore. Cancer.gov

11) Enlarged spleen or liver. These organs may swell from leukemia cell buildup, causing fullness under the ribs or early satiety. Cancer.gov

12) Weight loss and poor appetite. Cancer-related inflammation and the body’s stress response reduce hunger and increase energy use. Cancer.gov

13) Night sweats. Profuse sweating during sleep can be a sign of active disease and high cytokine levels. Cancer.gov

14) Skin lumps or rashes (leukemia cutis). Myeloid blasts can collect in the skin, forming painless nodules or plaques. Cancer.gov

15) Headache or neurologic symptoms. If blasts enter the fluid around the brain and spine, people may have headaches, confusion, or weakness. Cancer.gov

---

Diagnostic tests

A) Physical exam

1) General check and vital signs. The clinician looks for pallor, fever, fast heart rate, fast breathing, and signs of infection or bleeding. This baseline guides urgent care. Cancer.gov

2) Skin and mucosa inspection. The exam looks for petechiae, bruises, rashes, mouth ulcers, and gum swelling that suggest low platelets or leukemic infiltration. Cancer.gov

3) Lymph node and gum exam. Enlarged nodes and thickened, tender gums may point toward monocytic involvement or leukemia cutis. Cancer.gov

4) Abdominal palpation for liver and spleen. Feeling for organ enlargement gives clues to disease burden and helps plan imaging. Cancer.gov

B) Manual bedside maneuvers

5) Spleen percussion (Castell’s sign) and careful palpation. A simple bedside technique to detect an enlarged spleen that may need imaging confirmation. Cancer.gov

6) Brief neurologic screen. Checking strength, reflexes, and cranial nerves can uncover CNS involvement or treatment-related issues that require urgent imaging or lumbar puncture. Cancer.gov

C) Laboratory & pathologic studies

7) Complete blood count (CBC) with differential. Often shows anemia, low platelets, and too many immature white cells. This prompts urgent hematology referral. Cancer.gov

8) Peripheral blood smear. A pathologist reviews cell shapes under a microscope. Seeing myeloblasts supports suspected AML and helps rule out look-alikes. Cancer.gov

9) Bone-marrow aspiration. A liquid sample from the hip bone is examined for blast percentage, cell appearance, and quick tests like cytochemistry. It is essential for diagnosis. Cancer.gov

10) Bone-marrow core biopsy. A small cylinder of bone shows how cells are arranged, fibrosis, and overall disease involvement, complementing the aspirate. Cancer.gov

11) Flow-cytometry immunophenotyping. This test labels surface and cytoplasmic markers (e.g., CD34, CD13, CD33, MPO) to confirm myeloid blasts, define subtype, and measure measurable residual disease (MRD). ASH Publications

12) Conventional cytogenetics (karyotype). Looks at whole-chromosome changes (e.g., t(8;21), inv(16), complex karyotype). These strongly affect prognosis and treatment strategy. ASH Publications

13) FISH (fluorescence in situ hybridization). A faster way to detect key translocations or deletions when metaphases are few or results are urgent. ASH Publications

14) Molecular mutation panel (PCR/NGS). Detects NPM1, FLT3-ITD/TKD, IDH1/IDH2, CEBPA, RUNX1, TP53, and others. These results guide targeted drugs, risk group, and transplant choices. ASH Publications

15) Coagulation studies. PT, aPTT, fibrinogen, D-dimer check for bleeding risk and DIC—especially important when differentiation between AML subtypes is unclear at presentation. Cancer.gov

16) Chemistry and tumor-lysis labs. Uric acid, LDH, potassium, phosphate, calcium, creatinine assess cell-breakdown risk and organ function before starting therapy. Cancer.gov

D) Electrodiagnostic

17) 12-lead ECG. A baseline ECG is recommended before anthracycline-based therapy and during treatment if symptoms occur, to detect arrhythmias or QT issues. Portail VasculairePMC

E) Imaging

18) Abdominal ultrasound. Confirms liver and spleen size, looks for infiltration, and helps track response during care. Cancer.gov

19) Chest X-ray. Useful at diagnosis to look for infection, fluid overload, or mediastinal changes; it also informs immediate supportive care. Cancer.gov

20) MRI or CT brain (when neurologic symptoms are present). Detects bleeding, infection, or leukemic involvement of the CNS; guides urgent management. Cancer.gov

---

Non-pharmacological treatments

Physiotherapy & physical care

1. Energy-conserving activity plan
   Description: A therapist teaches you to spread tasks across the day, rest before you are exhausted, and use tools (like shower chairs).
   Purpose: Reduce fatigue while you keep independence.
   Mechanism: Balances activity with rest so limited red cells and oxygen use are not over-stressed.
   Benefits: Less breathlessness, safer daily life, more control.

2. Gentle aerobic walking
   Description: Short, paced walks on flat ground with a caregiver or in a clinic corridor.
   Purpose: Maintain heart-lung fitness and mood.
   Mechanism: Small, regular aerobic load improves circulation and reduces de-conditioning.
   Benefits: Better energy, sleep, and appetite.

3. Sit-to-stand strength drills
   Description: Short sets rising from a chair, using arms if needed.
   Purpose: Keep leg power for transfers and fall prevention.
   Mechanism: Recruits large muscle groups without heavy strain.
   Benefits: Safer mobility, more confidence.

4. Thera-band upper-limb work
   Description: Light resistance bands for biceps, triceps, and shoulder stabilizers.
   Purpose: Preserve reach, lift, and self-care ability.
   Mechanism: Low-load strength stimulus that is safe during low counts (with infection precautions).
   Benefits: Less muscle loss; easier dressing and hygiene.

5. Balance and gait training
   Description: Heel-to-toe walking, side steps, and stance drills with support bars.
   Purpose: Reduce falls if weak or dizzy.
   Mechanism: Trains vestibular and ankle strategies.
   Benefits: Fewer stumbles; safer home walking.

6. Breathing exercises & incentive spirometry
   Description: Slow deep breaths with a handheld spirometer or pursed-lip technique.
   Purpose: Prevent atelectasis and support oxygenation.
   Mechanism: Improves lung expansion and mucus clearance.
   Benefits: Less cough, fewer chest infections.

7. Gentle stretching & range-of-motion
   Description: Daily shoulder, neck, hip, and calf stretches.
   Purpose: Prevent stiffness from bed rest.
   Mechanism: Keeps soft tissues long and joints moving.
   Benefits: Less pain, easier movement.

8. Lymphatic self-drainage for swelling
   Description: Light, directional strokes taught by a therapist.
   Purpose: Manage limb or facial puffiness.
   Mechanism: Supports lymph flow when protein levels change.
   Benefits: Comfort, better fit of clothes and shoes.

9. Mucositis mouth care coaching
   Description: Non-drug oral routines (ice chips, soft toothbrush, bland rinses).
   Purpose: Ease mouth ulcers from chemo.
   Mechanism: Cooling and gentle hygiene reduce inflammation and germs.
   Benefits: Less pain, better eating.

10. Cancer-specific fatigue education
    Description: Teach the difference between “good tired” and warning tired.
    Purpose: Stop over-exertion that leads to crashes.
    Mechanism: Uses symptom diaries to match load to capacity.
    Benefits: More stable days.

11. Fall-proofing the home
    Description: Remove loose rugs, add grab bars and night lights.
    Purpose: Prevent injuries when platelets are low.
    Mechanism: Environmental safety reduces trip risks.
    Benefits: Fewer ER visits, peace of mind.

12. Pressure-injury prevention
    Description: Turn schedules, cushions, and skin checks.
    Purpose: Avoid bedsores during long stays.
    Mechanism: Off-loads bony areas and protects fragile skin.
    Benefits: Comfort and fewer infections.

13. Thermal comfort therapy
    Description: Warm layers, heated blankets, or cool packs as needed.
    Purpose: Ease chills or fever discomfort.
    Mechanism: Supports temperature comfort while neutropenic.
    Benefits: Better rest and mood.

14. Pelvic floor & cough-sneeze strategies
    Description: Teach gentle activation to avoid strain bleeding.
    Purpose: Protect pelvic support with thrombocytopenia.
    Mechanism: Neuromuscular control at low effort.
    Benefits: More comfort, fewer mishaps.

15. Return-to-activity ladder
    Description: A stepwise plan from bed exercises to light chores.
    Purpose: Guide safe progress after each chemo cycle.
    Mechanism: Graded exposure prevents boom–bust.
    Benefits: Measured recovery and confidence.

Mind-body, gene-informed, and educational therapies

16. Mindfulness-based stress reduction (MBSR)
    Description: Guided breath awareness and body scans 10–20 minutes/day.
    Purpose: Reduce anxiety, pain, and insomnia.
    Mechanism: Calms stress pathways (HPA axis), improves pain perception.
    Benefits: Better mood, focus, and coping.

17. Cognitive-behavioral therapy (CBT) for cancer
    Description: Short, focused sessions to reframe fear and uncertainty.
    Purpose: Lessen distress and improve adherence.
    Mechanism: Identifies unhelpful thoughts; builds coping behaviors.
    Benefits: Lower depression and better quality of life.

18. Meaning-centered counseling
    Description: Explore values, legacy, and goals.
    Purpose: Maintain hope and purpose through treatment.
    Mechanism: Strengthens meaning-making pathways.
    Benefits: Greater resilience and patient-reported wellbeing.

19. Relaxation & guided imagery
    Description: Audio scripts imagining calm scenes during infusions.
    Purpose: Ease nausea and procedure stress.
    Mechanism: Engages parasympathetic tone.
    Benefits: Lower nausea, less perceived pain.

20. Sleep hygiene program
    Description: Fixed wake times, light control, nap limits.
    Purpose: Restore sleep disrupted by steroids or stress.
    Mechanism: Resets circadian rhythms.
    Benefits: More energy, clearer thinking.

21. Nutritional education for neutropenia
    Description: Safe food handling and protein-first meals.
    Purpose: Prevent foodborne infection and weight loss.
    Mechanism: Limits microbe exposure; supports anabolism.
    Benefits: Fewer infections, better strength.

22. Caregiver skills training
    Description: Teach temperature checks, medication logs, and red-flag signs.
    Purpose: Early problem detection at home.
    Mechanism: Structured routines and checklists.
    Benefits: Faster help, fewer complications.

23. Gene-informed education session
    Description: Explain FLT3, NPM1, IDH1/2, TP53, KMT2A and why tests matter.
    Purpose: Help you understand targeted therapy choices.
    Mechanism: Converts complex reports into plain language.
    Benefits: Shared decisions with your team.

24. Financial and work navigation
    Description: Help with leave forms, insurance, and transport.
    Purpose: Reduce money stress that harms recovery.
    Mechanism: Practical problem-solving and resource links.
    Benefits: Better adherence and less worry.

25. Peer support & survivorship classes
    Description: Group sessions with patients and survivors.
    Purpose: Normalize feelings and share tips.
    Mechanism: Social modeling and support.
    Benefits: Hope, practical advice, and community.

---

Key drug treatments

(Typical adult dosing is shown to give context. Always follow your oncologist’s exact plan; doses change with age, organ function, genetics, and blood counts.)

1. Cytarabine (Ara-C) — antimetabolite chemotherapy
   Dose/time: Commonly 100–200 mg/m²/day by continuous IV on days 1–7 for induction (“7+3”), or very high dose 1–3 g/m² IV q12h in consolidation.
   Purpose/mechanism: Mimics a DNA building block and stops leukemia cell DNA synthesis, forcing cell death.
   Side effects: Low counts, fever, mucositis, rash, liver enzyme rise; high-dose can cause cerebellar toxicity and conjunctivitis (needs steroid eye drops).

2. Daunorubicin — anthracycline chemotherapy
   Dose/time: Often 60–90 mg/m² IV on days 1–3 with cytarabine.
   Mechanism: Intercalates DNA and inhibits topoisomerase II, causing breaks.
   Side effects: Myelosuppression, hair loss, mucositis; lifetime-dose-related heart damage risk—heart function is monitored.

3. Idarubicin — anthracycline
   Dose/time: ~12 mg/m² IV days 1–3 as an alternative to daunorubicin.
   Mechanism/benefits: Similar to daunorubicin; sometimes preferred in certain protocols.
   Side effects: As above, including cardiac and marrow effects.

4. CPX-351 (liposomal daunorubicin + cytarabine)
   Dose/time: IV on days 1, 3, 5 for induction in therapy-related AML or AML with myelodysplasia-related changes.
   Mechanism: Fixed molar ratio in liposomes targets blasts better and slowly releases drugs.
   Side effects: Prolonged low counts, infections; similar anthracycline cautions.

5. Venetoclax — BCL-2 inhibitor (targeted)
   Dose/time: Oral daily (ramp-up to 400 mg) with azacitidine or decitabine for older/unfit patients; cycles monthly.
   Mechanism: Frees cell death pathways by blocking BCL-2, making blasts die.
   Side effects: Tumor lysis (needs careful start), neutropenia, nausea; interacts with azoles (dose adjust).

6. Azacitidine — hypomethylating agent
   Dose/time: 75 mg/m² SC/IV daily days 1–7 every 28 days; often with venetoclax.
   Mechanism: Changes DNA methylation, reactivating silenced genes and slowing blasts.
   Side effects: Low counts, GI upset, injection site reactions.

7. Decitabine — hypomethylating agent
   Dose/time: 20 mg/m² IV days 1–5 every 28 days; also used in 10-day schedules with venetoclax.
   Mechanism/benefits: Similar to azacitidine; can be chosen based on logistics and response.
   Side effects: Myelosuppression, infections, fatigue.

8. Midostaurin — FLT3 inhibitor (targeted)
   Dose/time: 50 mg orally twice daily on days 8–21 of induction and consolidation with “7+3,” then as maintenance in FLT3-mutated AML.
   Mechanism: Blocks FLT3 signaling that drives blast growth.
   Side effects: Nausea, rash, low counts; monitor QT and drug interactions.

9. Gilteritinib — FLT3 inhibitor for relapsed/refractory AML
   Dose/time: 120 mg orally daily.
   Mechanism: Potent inhibition of FLT3-ITD/TKD mutant signaling.
   Side effects: Liver enzyme rise, differentiation syndrome (treat early with steroids), QT prolongation.

10. Ivosidenib — IDH1 inhibitor
    Dose/time: 500 mg orally daily (monotherapy or with azacitidine) for IDH1-mutant AML.
    Mechanism: Blocks mutant IDH1 and lowers 2-HG, allowing blasts to mature.
    Side effects: Differentiation syndrome, leukocytosis, QT prolongation; monitor chemistry.

11. Enasidenib — IDH2 inhibitor
    Dose/time: 100 mg orally daily for IDH2-mutant AML.
    Mechanism/benefits: Similar to ivosidenib but targets IDH2.
    Side effects: Differentiation syndrome, bilirubin rise, GI upset.

12. Gemtuzumab ozogamicin — anti-CD33 antibody-drug conjugate
    Dose/time: Commonly 3 mg/m² IV on days 1, 4, 7 (lower fractionated dosing) with induction or consolidation in CD33-positive AML.
    Mechanism: Antibody binds CD33; delivers calicheamicin toxin into blasts.
    Side effects: Liver veno-occlusive disease risk, infusion reactions, low counts.

13. Glasdegib — Hedgehog pathway inhibitor
    Dose/time: 100 mg orally daily with low-dose cytarabine (LDAC 20 mg SC twice daily days 1–10) for patients unfit for intensive chemo.
    Mechanism: Inhibits leukemic stem-cell signaling.
    Side effects: Taste change, muscle cramps, anemia, QT prolongation.

14. Low-dose cytarabine (LDAC)
    Dose/time: 20 mg SC twice daily days 1–10 each 28-day cycle; often with glasdegib or venetoclax.
    Mechanism: Same as Ara-C but gentler schedule for frail patients.
    Side effects: Low counts, injection site irritation.

15. Supportive antimicrobials (prophylaxis as ordered)
    Examples/dose: A fluoroquinolone, an azole antifungal, and acyclovir are commonly used during profound neutropenia per local protocols.
    Purpose/mechanism: Prevent bacterial, fungal, and viral infections when white cells are low.
    Side effects: Drug interactions (notably azoles with venetoclax), GI upset, QT issues.
    (These are not anti-leukemia drugs but are essential medicines in AML care.)

---

Dietary molecular supplements

1. High-quality whey or plant protein
   Dose: 20–30 g per serving, 1–2×/day as advised.
   Function/mechanism: Supplies amino acids (leucine) to rebuild muscle after chemo-related catabolism.
   Note: Avoid if kidney function is poor without clinician input.

2. Vitamin D3
   Dose: Commonly 800–2000 IU/day; replete if deficient per labs.
   Mechanism: Immune modulation and bone health.
   Caution: Do not exceed advised doses; monitor calcium.

3. Omega-3 fatty acids (EPA/DHA)
   Dose: 1–2 g/day combined EPA+DHA with food.
   Mechanism: Anti-inflammatory effects; may help appetite and weight.
   Caution: Platelet issues—coordinate with team.

4. Oral glutamine
   Dose: Often 10 g 2–3×/day during mucositis periods (if approved).
   Mechanism: Fuel for gut cells; may ease mouth sores.
   Caution: Not for everyone; discuss first.

5. Zinc (short-term if deficient)
   Dose: 15–30 mg elemental zinc/day for limited weeks.
   Mechanism: Supports taste and wound repair.
   Caution: Can lower copper with long use.

6. Melatonin (sleep aid)
   Dose: 2–5 mg 1–2 hours before bed.
   Mechanism: Regulates sleep; mild anti-oxidant actions reported.
   Caution: Check interactions; may cause morning grogginess.

7. Ginger (for nausea)
   Dose: 0.5–1 g/day divided (tea or capsules).
   Mechanism: Acts on GI motility and serotonin pathways.
   Caution: May affect bleeding—ask team.

8. Probiotics (generally avoided during neutropenia)
   Note: While helpful in some GI settings, AML patients with very low neutrophils are usually advised to avoid live probiotics due to rare bloodstream infection risk. Use only if your oncologist approves.

9. Curcumin (turmeric extract)
   Dose: If approved, standardized extract 500–1000 mg/day.
   Mechanism: Anti-inflammatory signaling.
   Caution: Strong drug-interaction potential; may thin blood—often not recommended during active chemo.

10. Green tea extract (EGCG)
    Dose: If approved, small standardized doses.
    Mechanism: Antioxidant pathways.
    Caution: Can interact with bortezomib-like drugs and affect liver enzymes—discuss before use.

---

Immunity/regenerative/stem-cell” medicines or modalities

(These are supportive or cellular treatments used under specialist care; some are procedures rather than classic “drugs.”)

1. Filgrastim (G-CSF)
   Dose: Typical 5 µg/kg SC daily after chemo until ANC recovers.
   Function/mechanism: Stimulates neutrophil production to shorten neutropenia.
   Notes: Bone pain common; timing varies by regimen.

2. Pegfilgrastim
   Dose: Single 6 mg SC dose per cycle (not used with very short cycles).
   Function: Long-acting G-CSF.
   Notes: Similar benefits/side effects to filgrastim.

3. Sargramostim (GM-CSF)
   Dose: As ordered SC/IV.
   Function: Broad myeloid growth factor; sometimes used post-transplant or infections.
   Notes: Fever, aches possible.

4. Intravenous immunoglobulin (IVIG)
   Dose: Weight-based infusions in select cases with recurrent infections and low IgG.
   Function: Passive antibodies to help fight infections.
   Notes: Headache, thrombosis risk; used selectively.

5. Allogeneic hematopoietic stem-cell transplantation (allo-HSCT)
   Function: Replaces diseased marrow with donor stem cells after high-dose conditioning.
   Mechanism: Donor immune system can attack residual leukemia (graft-versus-leukemia).
   Notes: Serious risks include graft-versus-host disease and infections, but it can cure some AML.

6. Donor lymphocyte infusion (DLI) after transplant
   Function: Boosts graft-versus-leukemia effect if minimal residual disease or relapse.
   Notes: Risk of GVHD; used with great care.

---

Procedures/surgeries (why they are done)

1. Central venous catheter or port placement
   Procedure: Minor surgery to place a long-term IV line.
   Why: Safe chemo delivery, blood draws, and transfusions.

2. Lumbar puncture ± intrathecal chemo
   Procedure: Needle into lower back to sample CSF; sometimes chemo is given into CSF.
   Why: Diagnose or treat CNS involvement.

3. Bone marrow biopsy/aspirate
   Procedure: Needle sample from pelvic bone.
   Why: Confirm AML, check genetics, and measure response.

4. Splenectomy (rare, selected cases)
   Procedure: Surgical removal of the spleen.
   Why: If spleen is massively enlarged with pain or destructive low platelets not responding to other care.

5. Allogeneic stem-cell transplantation
   Procedure: Conditioning chemo/radiation followed by donor stem-cell infusion.
   Why: Potentially curative in fit patients with suitable risk profiles.

---

Prevention and safety steps

1. Wash hands often; use alcohol gel when outside.

2. Check temperature daily during low counts; report fever ≥38.0°C immediately.

3. Follow neutropenia food safety: well-cooked foods, pasteurized dairy, washed/peeled produce.

4. Avoid crowds and sick contacts during nadirs; mask in clinics as advised.

5. Care for the mouth: soft brush, bland rinses; avoid flossing if platelets are very low unless cleared.

6. Protect skin: moisturize, treat cuts early, avoid shaving nicks (use electric razors).

7. Prevent falls: keep floors clear; wear supportive shoes; rise slowly.

8. Vaccinations: keep inactivated vaccines up to date as your team recommends; avoid live vaccines during immunosuppression.

9. Medicine list management: carry a list to avoid dangerous interactions (especially with azoles, venetoclax, QT-prolonging drugs).

10. Sun protection and hydration: some drugs increase photosensitivity; drink enough fluids unless on a restriction.

---

When to see doctors or get urgent help

• Fever ≥38.0°C, chills, or feeling suddenly unwell.

• Shortness of breath, chest pain, confusion, severe headache, or new weakness.

• Bleeding: nosebleed that won’t stop, blood in stool/urine, new big bruises, or petechiae.

• Mouth ulcers so painful you cannot drink; severe vomiting or diarrhea.

• Catheter redness, pus, or pain.

• Little urine or severe swelling; yellow eyes/skin; very dark urine.

• New rash, severe bone pain, or vision changes.

• Any new symptom that worries you—better to call early.

---

What to eat and what to avoid

1. Eat: Protein-first meals (eggs, fish, chicken, tofu, lentils) to maintain muscle.

2. Eat: Soft, moist foods if mouth is sore (soups, smoothies, yogurt—pasteurized).

3. Eat: Complex carbs (rice, oats, potatoes) for steady energy.

4. Eat: Healthy fats (olive oil, avocado, nuts if safe to chew).

5. Eat: Well-washed, peeled fruits/vegetables; cook when counts are very low.

6. Avoid: Raw or undercooked meats, fish (sushi), eggs; unpasteurized products.

7. Avoid: Salad bars, buffet foods, or anything sitting at room temperature.

8. Avoid: Herbal blends or supplements without team approval (interactions are common).

9. Avoid: Grapefruit and Seville orange with many targeted drugs (CYP3A interactions).

10. General: Drink safe, treated water; small frequent meals if nauseated.

---

Frequently asked questions

1. Is AML curable?
   Some people are cured, especially with favorable genetics and with the right combination of chemo, targeted therapy, and sometimes a stem-cell transplant. Your risk group and response guide the plan.

2. How fast does AML progress?
   AML is acute. Without treatment it worsens quickly. With prompt, modern care, many achieve remission.

3. What is remission?
   It means blasts are below defined limits and blood counts recover. You still need follow-up because relapse can occur.

4. Why do I need genetic tests on my leukemia?
   Genes like FLT3, NPM1, IDH1/2, TP53, KMT2A guide drug choices and transplant decisions.

5. Will I lose my hair?
   Many chemo drugs cause hair loss. It usually regrows after treatment.

6. Why are infections such a big risk?
   Chemo lowers white cells. Germs that are harmless normally can become serious now. Prevention and early antibiotics save lives.

7. What is differentiation syndrome?
   A sudden inflammatory reaction when targeted drugs (like IDH inhibitors) make blasts mature quickly. It causes fever, fluid in lungs, and low blood pressure. It is treatable if caught early—report symptoms at once.

8. What is tumor lysis syndrome?
   When many leukemia cells die at once and spill contents into blood, stressing kidneys and heart. Doctors prevent it with fluids and specific medicines.

9. Do targeted pills replace chemo?
   Sometimes, especially in older or unfit patients, targeted pills with hypomethylating drugs work very well. In other cases, intensive chemo is still best.

10. How is transplant decided?
    Your age, fitness, donor match, genetic risk, and response determine whether an allogeneic transplant is advised.

11. Can I work during treatment?
    Some can work part-time between cycles. Many need leave. Energy levels and infection risk guide choices.

12. What about fertility?
    Chemo can affect fertility. Discuss sperm banking or egg/embryo preservation before treatment if possible.

13. Can I exercise?
    Yes, light, supervised activity is encouraged. Stop if you feel dizzy, breathless, or if your team tells you to pause.

14. Are vaccines safe?
    Inactivated vaccines are used at the right times. Live vaccines are avoided during immunosuppression. Your team will time them.

15. What is the outlook for AML today?
    Outcomes keep improving thanks to targeted therapies, better infection prevention, and smarter use of transplant. Your personal plan is tailored to your biology and goals.

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: September 07, 2025.